In vitro transcription (IVT) for mRNA vaccines and therapeutics; capping, polyadenylation, and purification at phase-appropriate scales; encapsulation into lipid nanoparticles (LNPs) with reproducible physicochemical control; analytics spanning identity, integrity, potency, and immunogenicity; fill–finish and stability programs aligned to regulatory expectations. All executed within a unified digital QMS (ALCOA+), with submission-ready documentation at every phase.

A deliberate approach to mRNA programs

Messenger RNA is an information molecule, but in therapy it is more than sequence. It is a construct of specific length, capping architecture, and structural stability, delivered in a nanoparticle that protects and presents it. Success depends on making early design choices that can be defended downstream. We treat every program as a sequence-to-drug-product continuum: define the intended therapeutic dose, design an IVT process that can generate consistent transcripts, purify without undermining integrity, encapsulate into nanoparticles that meet pharmacology requirements, and finalize in a presentation that preserves potency across storage and delivery. At MycoVista, we avoid building complexity after the fact. Instead, we constrain choices early, align physical process parameters to the target product profile, and implement assays that allow developers, operators, and auditors to see the same reality.

Why teams run mRNA & LNP here

Therapeutic mRNA programs succeed when the molecule and the delivery system are engineered together. Running IVT in one place and outsourcing encapsulation elsewhere creates gaps that can sink timelines and weaken regulatory filings. Our integrated offering reduces that risk.

• End-to-end ownership: Sequence design, IVT, capping and tailing, purification, LNP encapsulation, analytics, fill–finish, and stability programs—all under one QMS spine.
• Platform optionality: Multiple encapsulation technologies (microfluidic mixing, ethanol injection, T-junction) selected based on scale, reproducibility, and regulatory fit.
• Phase-appropriate controls: Early programs run with agile screening; clinical and commercial supply is locked to reproducible CPP ranges with validated methods.
• Regulatory alignment: IND/IMPD/BLA text reflects actual methods and data, not templates. Each control is mapped from QTPP to CQAs to CPPs before development starts.

Background: constraints that actually matter

Most avoidable failures in mRNA programs trace to four themes: transcription constructs that stress IVT chemistry, purification strategies that damage integrity, encapsulation systems that drift across batches, and analytical stacks that don’t measure stability drivers. We mitigate these risks upstream. Sequence architecture is treated as a process parameter. Enzymatic conditions and capping efficiency are modeled realistically. LNP encapsulation is validated not only for encapsulation efficiency but also for reproducible particle size and polydispersity. Analytics are selected for clarity and reproducibility, not only to satisfy checklists but to inform real decisions.

Program spine: QTPP → CQAs → CPPs

Every project begins with a definition of what “good” means in measurable terms.

QTPP (intended product): route (IV, IM, inhaled), intended dose, presentation (vial or prefilled syringe), target shelf life, acceptable residuals (DNA template, enzymes, solvents, lipids), acceptable particle size window, sterility and endotoxin limits, pH and osmolality ranges.
CQAs (measured attributes): transcript length and integrity, capping efficiency, polyA tail length distribution, dsRNA content, potency (cell-based translation), LNP particle size and PDI, encapsulation efficiency, residual DNA/enzyme/solvent/lipid ratios, sterility, endotoxin, and stability readouts.
CPPs (controlled levers): template design, IVT enzyme ratios, reaction time and temperature, capping chemistry, purification conditions (chromatography membranes, flow rates, shear windows), LNP mixing flow rates and ratios, buffer composition, filtration and fill–finish parameters.

The link between QTPP, CQAs, and CPPs is written into protocols and batch records from day one. This control strategy becomes the foundation of every later submission.

IVT construct design and transcript engineering

A well-designed template reduces rework and risk downstream. At MycoVista, we build design into the process itself.

• 5’ Cap strategy: Choice of co-transcriptional capping analogs or enzymatic post-transcriptional methods is evaluated early; efficiencies are quantified, not assumed.
• Poly(A) tailing: Length distribution is engineered for translational stability, and variability is tracked as a CQA.
• UTRs and coding regions: Codon optimization is balanced against immunogenicity risk; untranslated regions are constrained to protect stability.
• Template production: DNA template supply is engineered with topology and residual control, ensuring IVT reactions start with high-quality input.

IVT process development

The chemistry of in vitro transcription is simple on paper but difficult in production. Our approach is to make it reproducible at scale.

• Enzyme ratios and kinetics: T7 RNA polymerase, capping enzymes, and tailing conditions are optimized within controlled windows.
• Reaction envelopes: Temperature, Mg²⁺, and buffer conditions are tuned for transcript integrity and yield.
• Shear and mixing: Reaction formats are designed to prevent local extremes that drive dsRNA artifacts.
• PAT (process analytical technology): Off-gas and spectroscopic signals are calibrated against transcript yield and purity, allowing real-time adjustments.

Purification and dsRNA removal

Purification is often the breaking point for mRNA programs. We design our purification stack to survive production scale.

• Capture: Chromatography methods (AEX, HIC, membrane-based) chosen for binding capacity and resolution.
• Polishing: Orthogonal steps tuned to reduce dsRNA and truncated transcripts without cutting into integrity.
• Buffer exchange: Conditions are locked for LNP compatibility and stability; pH and osmolality are tracked across steps.
• Residual control: DNA template, enzyme proteins, and solvents are measured and trended with prespecified acceptance windows.

LNP encapsulation

The delivery system is inseparable from the drug. We design LNP encapsulation processes with reproducibility in mind.

• Mixing platforms: Microfluidics for precision at small scale; scalable mixers for clinical and commercial batches. Each platform has CPPs documented.
• Encapsulation efficiency: Encapsulation efficiency and particle size are monitored in real time.
• Particle attributes: Size and PDI are treated as CQAs with prespecified limits. Potency readouts link directly to particle parameters.
• Lipid sourcing and QC: Each lipid component is qualified for purity, stability, and lot-to-lot consistency.

Analytics: measure what matters

Our analytic stack is built for clarity, not clutter.

• mRNA core panel: Integrity (capillary electrophoresis), length distribution, capping efficiency, polyA tail profiling, dsRNA content, residual DNA/protein/solvent, sterility, endotoxin.
• Potency: Cell-based translation assays aligned to therapeutic intent.
• LNP analytics: Particle size (DLS, NTA), encapsulation efficiency, PDI, zeta potential, stability tracking.
• In-process control: Positioned where they inform decisions, not as afterthoughts.
• Trending: Control charts for dsRNA, particle size, potency, and residuals, with predefined responses to drift.

Fill–finish and presentation

Drug product decisions define how therapy reaches patients. We align them to both biology and logistics.

• Buffers and excipients: Selected for stability and device compatibility, with clear rationales.
• Sterile filtration feasibility: Tested on real bulk; aseptic processing validated where filtration compromises potency.
• Presentations: Vials and prefilled syringes; lyophilization considered where stability justifies.
• Inspection and CCIT: Container closure integrity validated with statistical sampling plans.

Stability programs

Stability studies are tailored to real-world distribution, not abstract templates.

• Design: Real-time and accelerated conditions, stress mapping to degradation pathways, freeze-thaw cycle studies.
• Readouts: Potency retention, dsRNA accumulation, particle size stability, visual and particulate criteria.
• Shelf-life rationale: Data-driven assignments with periodic review and comparability studies for any container or process changes.

Validation, PPQ, and lifecycle

Validation at MycoVista is not a paperwork exercise—it is the translation of design into reproducibility.

• Design space to recipe: Development ranges flow into batch records with interlocks that matter.
• Clearance studies: DNA template clearance, dsRNA removal, and solvent residual studies sized to actual risk.
• Media fills and aseptic validation: Representative interventions included; results trended across runs.
• Cleaning validation: Surfaces and soils documented, with periodic verification built into lifecycle control.

Facilities and scale

Capabilities are transparent and sized to actual needs.

• Production: IVT and encapsulation skids from pilot to GMP scale; closed-system options available.
• Cleanrooms: ISO 8/7 with positive pressure flows; validated utilities for HPW, clean steam, compressed air.
• Analytics: qPCR/ddPCR, CE, HPLC, DLS/NTA, ELISA, potency assays, phase-appropriate LNP characterization.
• Digital systems: eBMR/eBR, ELN, LIMS, and CDS validated with audit trails and controlled access.

Regulatory and QMS posture

Our regulatory philosophy is to write files that read like clear narratives: what the product is, how it is made, how it is measured, and how changes are controlled.

• QbD alignment: QTPP to CQA to CPP linkage embedded in protocols and batch records.
• Digital QMS spine: Deviation, CAPA, change control, training, and investigations unified across both hubs.
• Comparability: Prespecified protocols for site, scale, or process changes, with orthogonal confirmation to protect filings.
• Authoring: CMC sections populated with data and tables, not adjectives, anticipating reviewer questions.

Program onboarding (first 30 days)

The first month defines program trajectory. We remove ambiguity early.

• QTPP → CQA → CPP mapping for mRNA and LNP.
• DoE plan covering IVT, purification, LNP encapsulation, and analytics.
• Gantt chart with decision gates to IND/registration; stability feasibility outlined.
• Written plan returned within 30 days, based on your provided data.

Indicative timelines

Feasibility: Template design brief, IVT test, purification screen, early LNP encapsulation feasibility.
Development: IVT DoE, dsRNA removal optimization, LNP particle consistency, potency assay qualification.
Engineering: Scale-similar IVT runs, encapsulation mass balance, stability enrollment, draft documentation package.
Lock: Process description finalized with CPP ranges, validation plans, comparability strategies.

Tech transfer and remediation

When programs arrive mid-stream, our first task is stabilization.

• Triage: IVT yields, dsRNA levels, purification deviations, encapsulation consistency, stability gaps.
• Gap mapping: Which CQAs lack control, which CPPs drift.
• Stabilize → optimize → lock: Interim setpoints, targeted DoE, comparability to bridge changes, lifecycle documentation updated.

Deliverables

Each engagement concludes with controlled artifacts.

• Control strategy and process description with CPP ranges.
• IVT package: mass balance, yield, dsRNA clearance, residuals.
• LNP package: encapsulation efficiency, particle size/PDI, stability data.
• Analytics files: methods, qualification, trending.
• Fill–finish and stability protocols with shelf-life rationale.
• Batch records and CMC text aligned to IND/IMPD/BLA requirements.

FAQ: mRNA & LNP Therapeutics

Do you support both co-transcriptional and enzymatic capping?
Yes. Strategy depends on development phase, efficiency targets, and filing posture. Co-transcriptional capping offers speed and simplicity for early phases; we quantify actual capping efficiency and residual cap analogs. Enzymatic post-transcriptional capping can deliver higher cap1/2 fidelity when regulators will scrutinize translation potency, and we include acceptance criteria tied to potency and innate immune activation. For both paths we lock CPPs such as Mg2+, temperature, enzyme ratios, reaction time, and quench conditions, then verify with cap-specific analytics and a translation assay aligned to mechanism.

How do you control dsRNA?
We remove dsRNA through an orthogonal purification stack and treat it as a CQA with explicit acceptance criteria. We screen membrane chromatography and polish conditions that reduce dsRNA while protecting integrity, then lock shear, residence time, and buffer windows. Release includes a phase-appropriate dsRNA readout with trending; any drift triggers predefined actions. We never assume template or enzyme choice alone will control dsRNA.

What LNP encapsulation platforms do you run?
We operate microfluidic mixers for precision at small and mid scales and scalable mixers for clinical and commercial volumes. Platform choice is based on reproducibility of particle size and PDI, encapsulation efficiency, cleaning validation, and operator reality. Each platform has defined CPPs (flow-rate ratio, total flow rate, temperature, lipid concentration, aqueous/organic composition) with guardrails tied to CQAs, and we demonstrate platform comparability before scale transitions.

Can you lyophilize mRNA–LNP products?
Yes, when supported by data. We run formulation screens to identify cryo- and lyoprotectants that preserve particle size, PDI, and potency after reconstitution. Cycle development is documented with critical parameters such as shelf temperature, chamber pressure, and primary/secondary drying endpoints. Any switch from liquid to lyo is managed by a comparability protocol and updated stability.

What if sterile filtration reduces potency?
We first determine whether potency loss is filter- or process-driven by running integrity-checked filters with controlled ∆P, temperature, and hold times. If filtration is genuinely detrimental, we validate aseptic operations with media fills that reflect real interventions and worst-case holds. Either way, the choice is documented with rationales, acceptance criteria, and operator-holdable instructions.

How do you manage DNA template quality for IVT?
Template DNA is treated like a product, not a reagent. We control host strain, fermentation mode, and lysis chemistry to maximize supercoiled content and minimize residuals. Downstream steps protect topology and remove RNA, gDNA, protein, and endotoxin. Release includes identity, topology distribution, residuals, and suitability for IVT. The template dossier links directly to IVT performance and dsRNA outcomes.

What is your potency strategy?
Potency methods map to therapeutic intent. For vaccines, we prioritize translation assays that quantify encoded protein expression with controls for cap status and tail length. For therapeutics, we add mechanism-appropriate cell-based function. We qualify methods phase-appropriately, trend potency versus particle attributes, and define predeclared actions for outliers.

How do you control particle size and PDI?
We run in-process DLS and confirm with orthogonal techniques as phase warrants. CPPs for mixing (flow-rate ratio, total flow rate), lipid composition, and temperature are set by DoE and then locked. Batches are trended with control charts for size, PDI, and encapsulation efficiency; excursions have predefined responses that operators can execute.

What does your stability program look like?
Stability is built around actual logistics. We design real-time and accelerated conditions with freeze-thaw studies and stress mapping to track dsRNA growth, potency retention, particle size drift, and visual/particulates. Shelf-life is assigned from data; any change in container, closure, or presentation triggers targeted studies and comparability.

How do you handle raw materials and lipid sourcing?
We qualify each lipid for purity, identity, and bioburden/endotoxin risk. Lot traceability is enforced in our digital QMS. For critical materials we dual-source or hold safety stock and document change-control plans. Any lipid supplier change is evaluated with risk-based comparability on particle attributes and potency.

What’s included in your QC release panel?
A phase-appropriate core set: mRNA identity and length distribution, integrity, capping efficiency, polyA profiling, dsRNA content, residual DNA/enzyme/solvent, sterility and endotoxin. For LNPs: particle size, PDI, encapsulation efficiency, and zeta potential as justified. We align method qualification/validation with program phase and keep clear acceptance criteria in the specifications file.

How do you approach scale-up without losing control?
We avoid “scale by luck.” We run scale-similar hydrodynamics, lock mixing regimes and residence times, and maintain identical ratios for aqueous/organic streams. A formal engineering run package documents mass balance, recovery, and attribute trending before PPQ. Operators receive batch records with interlocks and alarms that matter at production tempo.

Can you take over mid-stream programs?
Yes. We begin with a stabilization phase: triage of yields, dsRNA, particle drift, filtration feasibility, and stability gaps. We map CQAs lacking control and CPPs that drift, implement interim setpoints to stop failures, then run focused DoEs to lock the true drivers. Comparability bridges changes to protect filings.

How do you document and author for regulators?
Files read as straightforward narratives: what the product is, how it’s made, how it’s measured, and how sameness is demonstrated after change. QTPP → CQA → CPP linkages are visible in protocols and batch records. We provide tables, ranges, and statistics—no adjectives in place of data. Comparability plans are prespecified for site, scale, platform, or presentation changes.

What about cleaning validation and cross-contamination control?
We define worst-case soils for IVT and LNP equipment, establish MACO/PDE logic, and validate cleaning cycles with swab/rinse limits tied to analytical sensitivity. Equipment is dedicated or controlled via validated changeover; verification is scheduled and trended.

Can you support prefilled syringes as well as vials?
Yes, contingent on compatibility data. We evaluate container-closure interactions, extractables/leachables risk, and CCIT. Presentation changes are managed by comparability with stability to confirm potency and particle attributes are preserved.

Do you integrate a digital QMS across hubs?
Yes. Deviations/CAPAs, change control, training, investigations, eBMR/eBR, ELN, LIMS, and CDS run on a single validated spine with audit trails and controlled access. That unification shortens investigations, makes multi-site filings coherent, and reduces inspection friction.

What are typical first-30-day deliverables?
You receive a written control strategy mapping QTPP → CQAs → CPPs, a DoE plan for IVT, purification, encapsulation, and analytics, a Gantt with gates to IND/IMPD, and a stability feasibility outline. We also list required sponsor inputs and set decision criteria with dates.

Summary

Messenger RNA and lipid nanoparticles represent one of the fastest-growing therapeutic classes, with enormous potential across vaccines, oncology, rare diseases, and beyond. But with that promise comes complexity: fragile transcripts, sensitive chemistries, and encapsulation steps that can make or break the program. Success requires more than equipment or reagents—it requires a disciplined, integrated approach that anticipates regulatory scrutiny, respects the physics of the system, and delivers reproducibility from discovery to GMP.

At MycoVista, we don’t treat mRNA as a series of disconnected tasks. We treat it as a seamless continuum: from template design through IVT, capping, purification, dsRNA removal, and encapsulation into lipid nanoparticles, all the way to analytics, fill–finish, and long-term stability. Each stage is engineered against the target product profile, with every critical quality attribute (CQA) explicitly tied to the process parameters that control it. That linkage is documented in ways that regulators can follow, reviewers can trust, and operators can actually run without surprises.

This discipline is what sets MycoVista apart. Our teams build programs that are not only scientifically rigorous but also inspection-ready, reducing the risk of late-stage failure or regulatory pushback. We unify development under one digital QMS spine, ensuring that deviations, CAPAs, change controls, and training records align across sites. The result is not just a molecule—it is a reproducible, defensible product that scales cleanly, withstands inspection, and accelerates your path to clinic and commercialization.

If your mRNA program is ready to move forward, MycoVista offers the clarity and control to take it there. Share your latest data, and we will return a structured plan with explicit gates, success criteria, and timelines, giving you confidence that your therapeutic will not only advance but also endure.

Contact our team today at info@mycovistabiotech.com